Michael T. Lotze, M.D. FACS, is professor of surgery, immunology and bioengineering, and director of the DAMP Laboratories at the University of Pittsburgh Medical Center Hillman Cancer Center and joined Zai Lab’s Scientific Advisory Board in 2024.
Dr. Lotze is a clinician-scientist and tumor immunologist who brings to our Scientific Advisory Board rich expertise across the surgery, immunology and bioengineering fields. Notably, Dr. Lotze previously presided over the Society for Immunotherapy of Cancer where he launched both the Primer on Tumor Immunology as well as the SITC Clinical Immuno-Oncology Network to advance rigorous and robust clinical protocols in cancer immunotherapy. He is the co-inventor of numerous patents in dendritic cell vaccines and antigen discovery and tumor infiltrating lymphocyte therapy.
He is an award-winning National Cancer Institute-trained scientist, formerly served as the inaugural director of Surgical Oncology at the University of Pittsburgh, was a former vice president of research at GlaxoSmithKline and is the founding director of the of the University of Pittsburgh Medical Center Hillman Cancer Center Academy (formerly UPCI Academy). Additionally, Dr. Lotze currently serves as editor in chief of the Journal for Immunotherapy of Cancer.
Dr. Lotze received his M.D. from Northwestern University Medical School and completed his surgical residency at Strong Memorial Hospital and surgical fellowship at the National Cancer Institute.
